LABELS · 1086d646-36dd-465c-ab6d-fc4e3b51115b

CELESTONE SOLUSPAN

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-03-06
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of CELESTONE SOLUSPAN Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of CELESTONE SOLUSPAN Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. CELESTONE SOLUSPAN Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).

Full extracted label fields

application numbers

NDA014602

boxed warning exact

brand names

CELESTONE SOLUSPAN

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf78d1be-42d7-4837-92a5-49113a79278f

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

1086d646-36dd-465c-ab6d-fc4e3b51115b

indications and usage exact

INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of CELESTONE SOLUSPAN Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of CELESTONE SOLUSPAN Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. CELESTONE SOLUSPAN Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).

indications and usage tables exact

is original packager

true

manufacturer names

Organon LLC

matched search terms

cancer
lymphomas
tumor
tumors

package ndcs

78206-118-01

product ndcs

78206-118

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRA-ARTICULAR
INTRALESIONAL
INTRAMUSCULAR
SOFT TISSUE

rxcuis

578803
578806

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 643
end exclusive: true
exact text: INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital a
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 0

current approval status

not_reconciled

duplicate text group

dup-50560ab267d97b0a3fab

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-710dee2f4b75a138b391

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

end: 139
end exclusive: true
exact text: is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 40

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 443
end exclusive: true
exact text: INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 810
end exclusive: true
exact text: ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenoc
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 244

current approval status

not_reconciled

duplicate text group

dup-0b67f127a6c466525df7

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-241ec0761450313554f9

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 610
end exclusive: true
exact text: Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 444

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 928
end exclusive: true
exact text: sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infan
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 411

current approval status

not_reconciled

duplicate text group

dup-563d33d468ff1366cf05

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-72861366b61d0ebc8997

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 728
end exclusive: true
exact text: Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 611

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1032
end exclusive: true
exact text: osis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 529

current approval status

not_reconciled

duplicate text group

dup-849ca71596fee38bfd9d

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-672cdd448fbc980f1888

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 832
end exclusive: true
exact text: Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 729

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1193
end exclusive: true
exact text: ngenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 633

current approval status

not_reconciled

duplicate text group

dup-f67ada5eb560e5012365

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-68145b0b4d6afb57ffc9

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 993
end exclusive: true
exact text: Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 833

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1323
end exclusive: true
exact text: econdary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic o
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 794

current approval status

not_reconciled

duplicate text group

dup-67365d328b0d08dd7554

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-78337959eba294ab237c

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1123
end exclusive: true
exact text: Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 994

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1479
end exclusive: true
exact text: nfancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplas
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 924

current approval status

not_reconciled

duplicate text group

dup-0ce735f2f07b8bee4d10

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-86c03ae88fd792ca58d2

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1279
end exclusive: true
exact text: Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1124

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1671
end exclusive: true
exact text: regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1080

current approval status

not_reconciled

duplicate text group

dup-e255668d3ff6247bc350

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-244bab264135eb02d607

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1471
end exclusive: true
exact text: Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1280

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1745
end exclusive: true
exact text: openia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteriti
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1272

current approval status

not_reconciled

duplicate text group

dup-72bcd737cecade900c7d

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-02ce3ed5d7bf3310e146

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1545
end exclusive: true
exact text: Neoplastic Diseases For palliative management of leukemias and lymphomas.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1472

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1883
end exclusive: true
exact text: t, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of p
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1346

current approval status

not_reconciled

duplicate text group

dup-bc67ada886a946783d48

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-7568b3a517e4d49cd5e9

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
1682
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start
1646
context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
1682
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start
1646

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1683
end exclusive: true
exact text: Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1546

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2031
end exclusive: true
exact text: iseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmon
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1484

current approval status

not_reconciled

duplicate text group

dup-aa3addd0476b99753b06

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-4c0646b2c22ebbc1382c

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1831
end exclusive: true
exact text: Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1684

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2162
end exclusive: true
exact text: th primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptoma
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1632

current approval status

not_reconciled

duplicate text group

dup-c36157db98a2efb6d15b

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-f9fcf06b5f942e337e32

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1962
end exclusive: true
exact text: Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1832

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2378
end exclusive: true
exact text: lar inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spon
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1763

current approval status

not_reconciled

duplicate text group

dup-3972d0764ea619a76414

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-95ba7ac512f61891a55f

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2178
end exclusive: true
exact text: Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1963

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2728
end exclusive: true
exact text: ases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of CELESTONE SOLUSPAN Injectable Suspension is indicated as adj
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 1979

current approval status

not_reconciled

duplicate text group

dup-e15189c1a20c2312a2fc

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-a3ca8893fc30677bdc0c

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2528
end exclusive: true
exact text: Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2179

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2814
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of CELESTONE SOLUSPAN Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episo
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2329

current approval status

not_reconciled

duplicate text group

dup-58264c9989c274a7d15c

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-a88bfe74241276e963cb

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2614
end exclusive: true
exact text: For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2529

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · positive indication candidate

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3187
end exclusive: true
exact text: oid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of CELESTONE SOLUSPAN Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of CELESTONE SOLUSPAN Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2415

current approval status

not_reconciled

duplicate text group

dup-8f1b59f2fb119949034f

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-6e6d9a33d8502cea11a4

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

end: 2721
end exclusive: true
exact text: is indicated
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2709

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2987
end exclusive: true
exact text: The intra-articular or soft tissue administration of CELESTONE SOLUSPAN Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2615

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 17 · positive indication candidate

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3451
end exclusive: true
exact text: atient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of CELESTONE SOLUSPAN Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. CELESTONE SOLUSPAN Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2788

current approval status

not_reconciled

duplicate text group

dup-76bcc015aabd26d928b7

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-1cb9bac1bb9053ee7cb0

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

end: 3077
end exclusive: true
exact text: is indicated
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 3065

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 3335
end exclusive: true
exact text: The intralesional administration of CELESTONE SOLUSPAN Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum.
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 2988

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 18 · unclassified context

application numbers

NDA014602

brand names

CELESTONE SOLUSPAN

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3451
end exclusive: true
exact text: localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. CELESTONE SOLUSPAN Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 3136

current approval status

not_reconciled

duplicate text group

dup-6d202fe55c741ba39e09

extraction review status

automated_candidate_pending_source_review

generic names

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

ind-span-b4d5d218bd332081a16f

label id

1086d646-36dd-465c-ab6d-fc4e3b51115b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 3451
end exclusive: true
exact text: CELESTONE SOLUSPAN Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: 1086d646-36dd-465c-ab6d-fc4e3b51115b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 435114226b81d7093fc8dbccfbbc0000e7144da7266bf6d4053c4a9038f2209e
start: 3336

source url

https://api.fda.gov/drug/label.json?search=id%3A%221086d646-36dd-465c-ab6d-fc4e3b51115b%22

spl effective date

2026-03-06

spl set id

bf78d1be-42d7-4837-92a5-49113a79278f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice